Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 7, 2007 - Issue 4
Submit an article Journal homepage
62
Views
8
CrossRef citations to date
0
Altmetric
Drug Profile

Desmoteplase in the treatment of acute ischemic stroke

Rima M Dafer Assistant Professor, Loyola University Chicago Stritch School of Medicine, Department of Neurology, 2160 South First Ave, Maywood, IL 60163, USA. [email protected]
&
José Biller Professor and Chair, Loyola University Chicago Stritch School of Medicine, Department of Neurology, 2160 South First Ave, Maywood, IL 60163, USA. [email protected]
Pages 333-337 | Published online: 09 Jan 2014

References

  • No authors listed. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med333, 1581–1587 (1995).
  • No authors listed. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke31, 2912–2919 (2000).
  • Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet363, 768–774 (2004).
  • Nicole O, Docagne F, Ali C, Margaill I et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med.7, 59–64 (2001).
  • Traynelis SF, Lipton SA. Is tissue plasminogen activator a threat to neurons? Nat. Med.7, 17–18 (2001).
  • Werf FVD. The ideal fibrinolytic: can drug design improve clinical results? Eur. Heart J.20, 1452–1458 (1999).
  • Hawkey C. Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature211, 434–435 (1966).
  • Cartwright T. The plasminogen activator of vampire bat saliva. Blood43, 317–326 (1974).
  • Gardell SJ, Friedman PA. Vampire bat salivary plasminogen activator. Methods Enzymol.223, 233–249 (1993).
  • Kruithof EK, Schleuning WD. A comparative study of amyloid-β (1–42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator. Thromb. Haemost.92, 559–567 (2004).
  • Epple G, Schleuning WD, Kettelgerdes G, Kottgen E, Gessner R, Praus M. Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2. J. Thromb. Haemost.2, 962–968 (2004).
  • Zavalova LL, Basanova AV, Baskova IP. Fibrinogen-fibrin system regulators from bloodscuckers. Biochemistry (Mosc.)67, 135–142 (2002).
  • Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb. Haemost.74, 387–390 (1995).
  • Toschi L, Bringmann P, Petri T, Donner P, Schleuning WD. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur. J. Biochem.252, 108–112 (1998).
  • Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood79, 1213–1217 (1992).
  • Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation90, 421–426 (1994).
  • Muschick P ZD, Donner P, Witt W. Thrombolytic properties of Desmodus (vampire bat) salivary plasminogen activator DSP1, Alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. Fibrinolysis7, 284–290 (1993).
  • Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke36, 66–73 (2005).
  • Furlan AJ, Eyding D, Albers GW et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37, 1227–1231 (2006).
  • Reddrop C, Moldrich RX, Beart PM et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke36, 1241–1246 (2005).
  • López-Atalaya JP RB, Levrat D, Nicole O et al. Molecular requirements for modulation of NMDA receptor signaling by tissue-type plasminogen activator. Proceedings of the 18th International Congress on Fibrinolysis and Proteolysis (ICFP). Proteolysis in the Postgenomic Era. San Diego, CA, USA (2006).
  • Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke34, 537–543 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.